Primordial dwarfism and slender bone disorder
MONDO:0800063A skeletal dysplsia characterized by primordial dwarfism, an extreme growth deficiency disorder that has its onset during embryonic development and persists throughout life and slender bone disorder, a heterogeneous group of neonatal dwarfism syndromes, usually of unknown etiology, associated with gracile (thin) bones, multiple fractures, and prenatal or early postnatal death.
9 clinical trials for this condition and its sub-types, 0 tagged with Primordial dwarfism and slender bone disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Primordial dwarfism and slender bone disorder
-
IMAGe syndrome 5 trials
-
Kenny-Caffey syndrome 0 trials · 4 incl. sub-types
2 sub-types
-
Lowry-Wood syndrome 1 trial
-
Roifman syndrome 1 trial
-
Microcephalic osteodysplastic primordial dwarfism types I and III 0 trials · 1 incl. sub-types
2 sub-types
-
3M syndrome 1 0 trials
-
3M syndrome 2 0 trials
-
3M syndrome 3 0 trials
-
Hallermann-Streiff syndrome 0 trials
-
Rothmund-Thomson syndrome type 3 0 trials
-
Seckel syndrome 10 0 trials
-
Seckel syndrome 2 0 trials
-
Seckel syndrome 5 0 trials
-
Seckel syndrome 8 0 trials
-
Seckel syndrome 9 0 trials
-
1 sub-type
- Bilateral generalized polymicrogyria 0 trials
-
Osteocraniostenosis 0 trials
-
New drug DSB2455 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called DSB2455 in adults with advanced cancers (breast, ovarian, prostate, pancreatic, or brain metastases) that have a specific DNA repair problem. The main goals are to check safety and see if the drug shrinks tumors. About 180 participan…
Phase 1 • Sponsor: Duke Street Bio Ltd • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug combo hopes to tackle Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new oral drug called SYN818 combined with olaparib in 110 adults with advanced solid tumors, including ovarian and breast cancers that have BRCA mutations or related DNA repair problems. The main goals are to find a safe dose and check for side effe…
Phase 1 • Sponsor: Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Jun 26, 2026 14:17 UTC
-
1,000 women with ovarian cancer to help unlock genetic treatment clues
Knowledge-focused Recruiting nowThis study follows 1,000 women newly diagnosed with epithelial ovarian cancer to see how their genetic makeup (BRCA and HRD status) influences their response to standard treatments. Researchers will track surgery outcomes, treatment response, and survival. The goal is to gather r…
Sponsor: Nordic Society of Gynaecological Oncology - Clinical Trials Unit • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
New registry aims to unlock secrets of rare dwarfism disorders
Knowledge-focused Recruiting nowThis study creates a registry to collect health information from 200 people with rare forms of primordial dwarfism, such as MOPDII and Meier-Gorlin syndrome. Researchers hope to learn how these conditions change over a person's lifetime and improve future care. Participants provi…
Sponsor: Nemours Children's Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Can a simple test predict ovarian cancer treatment success?
Knowledge-focused Recruiting nowThis study is testing two genetic tests (Giscar and myChoice) to see if they can identify ovarian cancer patients whose tumors have a specific DNA repair problem (HRD). The goal is to see if these tests can predict which patients will respond well to platinum chemotherapy and may…
Phase 2 • Sponsor: Centre Francois Baclesse • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:47 UTC